Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

Key Points

• Voyager Therapeutics reported a loss of $0.57 EPS for the quarter, missing analysts' estimates by $0.09, with revenue of $5.20 million against an expected $9.50 million.
• The company's stock has seen a recent target price downgrade from $9.00 to $8.00 by Wedbush, but it currently holds a consensus rating of "Buy" with an average target price of $13.25.
• Institutions now hold 48.03% of Voyager Therapeutics’ shares, with notable increases in stakes from several hedge funds and investors.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09), Zacks reports. The company had revenue of $5.20 million during the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.

Voyager Therapeutics Stock Performance

Shares of VYGR stock traded down $0.08 on Friday, reaching $3.14. 1,225,068 shares of the company's stock traded hands, compared to its average volume of 781,033. The business's 50 day moving average price is $3.23 and its two-hundred day moving average price is $3.64. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $8.27. The company has a market capitalization of $174.18 million, a P/E ratio of -1.70 and a beta of 0.90.

Analyst Upgrades and Downgrades

Separately, Wedbush decreased their target price on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Thursday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $13.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in Voyager Therapeutics by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock valued at $3,474,000 after purchasing an additional 11,929 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Voyager Therapeutics in the first quarter worth about $218,000. Acadian Asset Management LLC lifted its position in shares of Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.